newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / Reuters

Pfizer sold nearly $6.4 billion of Vyndamax and related drugs in 2025.

Pfizer's Vyndamax patent protection in the U.S. is extended until June 1, 2031.

KEY POINTS
COMPANIES
Read the full story on Reuters →
Share X LinkedIn

Summarized by Newsio from Reuters. How we summarize →